Immutep Limited (ASX: IMM)
Australia
· Delayed Price · Currency is AUD 0.305
+0.020 (7.02%)
Nov 22, 2024, 4:10 PM AEST
Immutep Revenue
In the fiscal year ending June 30, 2024, Immutep had annual revenue of 3.84M AUD with 9.59% growth. Immutep had revenue of 1.73M in the half year ending June 30, 2024, a decrease of -34.22%.
Revenue
3.84M
Revenue Growth
+9.59%
P/S Ratio
95.37
Revenue / Employee
123.93K
Employees
31
Market Cap
443.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
| Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
| Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
| Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
| Jun 30, 2020 | 13.74M | 8.10M | 143.72% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 22.18B |
| ResMed Inc. | 6.93B |
| Pro Medicus Limited | 161.50M |
| Fisher & Paykel Healthcare Corporation Limited | 1.60B |
| Cochlear Limited | 2.24B |
| Sonic Healthcare Limited | 8.97B |
| Ramsay Health Care Limited | 16.66B |
| Telix Pharmaceuticals Limited | 645.68M |
Immutep News
- 8 days ago - Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients - Seeking Alpha
- 9 days ago - Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial - Benzinga
- 9 days ago - Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer - GlobeNewsWire
- 25 days ago - Immutep Quarterly Activities Report Q1 FY25 - GlobeNewsWire
- 6 weeks ago - Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 6 weeks ago - Immutep: Navigating The Bumps In The Road - Seeking Alpha
- 2 months ago - Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer - GlobeNewsWire
- 2 months ago - Immutep Ltd Clinical Results Webinar Transcript - GuruFocus